News
Here you can read the latest news regarding Inven2s portfolio businesses, innovation projects and clinical studies. Every month we write longer articles in which we interview current researchers and clinicians.
Authera lands collaborative agreement with argenx
The platform company Authera, spun out of research at the University of Oslo and Oslo University Hospital, reports that they have entered into a...
Technology from the University of Oslo is on its way to the moon.
In 2012, we licensed out technology from the University of Oslo to the Norwegian space technology company Eidel. Now this technology is on its way...
Summary of 2022
In 2022, we were delighted to reach yet another level in our long-term innovation work and, not least, to note that a record number of clinical...
Will revolutionise CAR-T therapy with a Norwegian licence
In April 2021, the Dutch company CellPoint in-licensed a CD37 CAR from Inven2. It is a kind of cell therapy for treating blood cancer developed by...
Vital licences
Inven2 has long experience of licence agreements, particularly in life sciences, which dominate the portfolio. The available licences are presented...
A unique biological super-taxi has been developed
Most protein-based therapeutics must be injected to be effective. That is both stressful for the patient and costly for the healthcare system....
Clinical studies – important for Norwegian companies
Inven2 handles agreements for clinical studies on behalf of the Cancer Clinic at Oslo University Hospital for most Norwegian companies that develop...
First in the world with unique immunotherapy
Zelluna Immunotherapy receives NOK 83 million from investors and the Research Council of Norway to continue its work on a new form of cancer...
SJJ Solutions signs industry development agreement with Inven2
The Dutch medical device company SJJ Solutions, the Department of Ophthalmology at Oslo University Hospital and the Laboratory of Adaptive Immunity...
Inven2 celebrates its 10th anniversary
Inven2 is 10 years in 2020. ‘I’m proud of what we have achieved over these ten years. I’m particularly proud of the fact that we have contributed to...
